Mirum HDV Trial Success Adds New Late Stage Growth Option [Yahoo! Finance]
Mirum Pharmaceuticals, Inc. - common stock (MIRM)
Last mirum pharmaceuticals, inc. - common stock earnings: 3/12 04:02 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
Mirum Pharmaceuticals (NasdaqGM:MIRM) reported positive primary endpoint results from its Phase 2b AZURE-1 study of brelovitug in chronic hepatitis delta virus (HDV). The trial showed robust antiviral activity and normalization of ALT levels, a key marker of liver inflammation. The company indicated that these data support advancing brelovitug toward a Phase 3 study in HDV. For Mirum Pharmaceuticals, which focuses on rare and serious liver diseases, the AZURE-1 readout adds a new clinical milestone to its pipeline story. HDV is a difficult-to-treat infection with limited therapeutic options, so the reported antiviral activity of brelovitug and ALT normalization are likely to draw close attention from clinicians and investors who track specialty hepatology drug development. Looking ahead, the main consideration for you as an investor is how the potential progression to Phase 3 might influence Mirum's development priorities, partnering opportunities, and funding needs. The AZUR
Show less
Read more
Impact Snapshot
Event Time:
MIRM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MIRM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MIRM alerts
High impacting Mirum Pharmaceuticals, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
MIRM
News
- Mirum Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026Business Wire
- Mirum Pharmaceuticals (MIRM) had its price target raised by Stifel Nicolaus from $125.00 to $130.00. They now have a "buy" rating on the stock.MarketBeat
- Assessing Mirum Pharmaceuticals (MIRM) Valuation After Strong Shareholder Returns And Rare Disease Pipeline Progress [Yahoo! Finance]Yahoo! Finance
- Mirum Pharmaceuticals (MIRM) had its price target raised by Robert W. Baird from $95.00 to $112.00. They now have an "outperform" rating on the stock.MarketBeat
- Mirum Pharmaceuticals (MIRM) had its "buy" rating reaffirmed by HC Wainwright.MarketBeat
MIRM
Earnings
- 2/25/26 - Miss
MIRM
Sec Filings
- 4/27/26 - Form SCHEDULE
- 4/27/26 - Form 8-K
- 4/24/26 - Form ARS
- MIRM's page on the SEC website